The 89% specificity of serum CEA has been considered too low for use as a single marker for general screening for colon cancer; however, serum CEA recently showed promise for colon cancer screening when used as part of a multianalyte test that combined CEA together with mutation detection from circulating tumor DNA, which showed a 99% specificity.24, 25, 26 This multianalyte panel detected ≈63% of stage I–III CRCs, suggesting an opportunity for additional contribution by markers such as CCSP‐2 that show high sensitivity to early stage CRC. This evidence concerns the gene SCGB1A1 and colonic neoplasm.